Sign up
Log in
UPDATE 2-Diagnostics firm Labcorp weighs ramping up mpox testing capacity
Share
Listen to the news
UPDATE 2-Diagnostics firm Labcorp weighs ramping up mpox testing capacity

Adds details on other tests from paragraph 6

By Sneha S K

- Diagnostics firm Labcorp LH.N said it is working with U.S. health regulators to determine if it to ramp up its mpox testing capacity, as countries outside Africa detect a type of the virus for the first time.

The company is processing approximately 500 mpox tests a month but can scale up to around 25,000 if , Marcia Eisenberg, Labcorp's chief scientific officer, told Reuters in an emailed statement.

A form of the virus has triggered global concern as it seems to spread easily though routine close contact, prompting the World Health Organization to declare mpox a global public health emergency this month.

Since then, Sweden and Thailand have confirmed cases of the clade Ib type of the virus, outside of the Democratic Republic of Congo and countries.

Labcorp makes a PCR test to detect mpox. It recently gained U.S. clearance for a home collection kit that it said doctors could soon order for patients 18 years or older who are suspected of mpox infection.

Other companies such as Roche ROG.S have said they were working to enhance laboratory testing capacity for mpox worldwide.

Roche, in an emailed statement, said it continues to monitor the situation to assess testing and said its production capacities "are designed to meet fluctuating global demand".

The Swiss company said it was working with regulators in Africa on their response plans.

"We are working together to assess how to leverage existing HIV program infrastructure to integrate testing into more disease areas, including mpox," Roche said.

U.S. laboratory operator Quest Diagnostics DGX.N also offers a mpox test, while Abbott Laboratories ABT.N makes the Alinity m test kit, which is authorized for U.S. emergency use for mpox.


(Reporting by Sneha S K in Bengaluru; Editing by Alan Barona and Krishna Chandra Eluri)

((Sneha.SK@thomsonreuters.com))

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.